# L9LS-R21 Interaction

> **NCT07208760** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Single dose of 1800 mg L9LS SC (12mL)
- **OTHER:** Placebo 12 mL SC
- **DRUG:** Single dose of 225 mg L9LS SC (1.5mL)
- **OTHER:** Placebo 1.5 mL SC

## Key facts

- **NCT ID:** NCT07208760
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-03
- **Primary completion:** 2028-03
- **Final completion:** 2029-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** After careful review of R21 interaction data that recently became available from a previous L9LS infant study, the study team has made the decision to not move forward with this protocol.
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07208760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07208760, "L9LS-R21 Interaction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07208760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*